Daily FNArena News

While brokers in the FNArena databse favour Sell ratings on Sigma Pharmaeceutical, Morgan Stanley has gone against the trend and upgraded to an Overweight rating.

While its share price has risen strongly over the past year Imdex continues to offer value and with earnings risk to the upside Moelis rates the stock a Buy.

A snapshot of economist responses to the weakest quarter since the 1991 recession and its implication for monetary policy.

Bradken surprised the market yesterday with a $162m capital raising and both Credit Suisse and Deutsche Bank have downgraded to Hold ratings on the news.

Daily update on share prices and consensus price targets.

A site visit by brokers to a UGL rail facility showed some possibilities but also highlighted an increasingly competitive market.

The Chartist cannot get too excited about short term prospects for Santos shares.

Charter Hall Office now intends to sell all of its US assets and return capital to shareholders, a move that has brokers split on whether or not the stock offers value at current levels.

Brokers predict which stocks will be promoted/relegated from the various S&P/ASX indices in June.

Daily update on share prices and consensus price targets.